Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free HOWL Stock Alerts

Werewolf Therapeutics (HOWL) Competitors

Werewolf Therapeutics logo
$0.68 -0.01 (-1.45%)
As of 02:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

HOWL vs. CNTB, ACOG, IMDX, IPHA, and HURA

Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Connect Biopharma (CNTB), Alpha Cognition (ACOG), Oncocyte (IMDX), Innate Pharma (IPHA), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Werewolf Therapeutics compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

In the previous week, Werewolf Therapeutics had 7 more articles in the media than Connect Biopharma. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.45 beat Werewolf Therapeutics' score of -0.71 indicating that Connect Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Connect Biopharma
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Werewolf Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Connect Biopharma has higher earnings, but lower revenue than Werewolf Therapeutics. Connect Biopharma is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Connect Biopharma$60K2,341.81-$55.48M-$1.00N/A
Werewolf Therapeutics$1.88M17.58-$60.82M-$1.36N/A

Connect Biopharma has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Connect Biopharma presently has a consensus target price of $8.67, indicating a potential upside of 248.62%. Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 451.47%. Given Werewolf Therapeutics' higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Connect Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Connect Biopharma
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

Connect Biopharma's return on equity of -88.21% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Connect BiopharmaN/A -88.21% -74.26%
Werewolf Therapeutics N/A -158.82%-69.75%

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Connect Biopharma and Werewolf Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Werewolf Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -202.23%. Alpha Cognition's return on equity of -55.71% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Cognition-202.23% -55.71% -43.78%
Werewolf Therapeutics N/A -158.82%-69.75%

Alpha Cognition currently has a consensus price target of $16.00, suggesting a potential upside of 157.23%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 451.47%. Given Werewolf Therapeutics' higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Alpha Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Cognition
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, Werewolf Therapeutics had 2 more articles in the media than Alpha Cognition. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 7 mentions for Alpha Cognition. Alpha Cognition's average media sentiment score of 0.33 beat Werewolf Therapeutics' score of -0.71 indicating that Alpha Cognition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alpha Cognition
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Werewolf Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Alpha Cognition has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

64.8% of Werewolf Therapeutics shares are held by institutional investors. 14.0% of Alpha Cognition shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alpha Cognition has higher revenue and earnings than Werewolf Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Cognition$10.22M13.25-$20.67M-$1.16N/A
Werewolf Therapeutics$1.88M17.58-$60.82M-$1.36N/A

Summary

Alpha Cognition beats Werewolf Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

55.4% of Oncocyte shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 2.1% of Oncocyte shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Werewolf Therapeutics has a net margin of 0.00% compared to Oncocyte's net margin of -1,238.52%. Oncocyte's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncocyte-1,238.52% N/A -79.78%
Werewolf Therapeutics N/A -158.82%-69.75%

Oncocyte has higher revenue and earnings than Werewolf Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncocyte$4.05M36.86-$50.22M-$1.62N/A
Werewolf Therapeutics$1.88M17.58-$60.82M-$1.36N/A

In the previous week, Werewolf Therapeutics had 9 more articles in the media than Oncocyte. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 0 mentions for Oncocyte. Oncocyte's average media sentiment score of 1.90 beat Werewolf Therapeutics' score of -0.71 indicating that Oncocyte is being referred to more favorably in the media.

Company Overall Sentiment
Oncocyte Very Positive
Werewolf Therapeutics Negative

Oncocyte currently has a consensus price target of $12.00, suggesting a potential upside of 158.62%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 451.47%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Oncocyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncocyte
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

Oncocyte has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Summary

Werewolf Therapeutics beats Oncocyte on 10 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Innate Pharma?

Werewolf Therapeutics (NASDAQ:HOWL) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Innate Pharma's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -158.82% -69.75%
Innate Pharma N/A N/A N/A

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Innate Pharma has higher revenue and earnings than Werewolf Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M17.58-$60.82M-$1.36N/A
Innate Pharma$10.19M13.36-$55.64MN/AN/A

In the previous week, Werewolf Therapeutics had 8 more articles in the media than Innate Pharma. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.59 beat Werewolf Therapeutics' score of -0.71 indicating that Innate Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Werewolf Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Innate Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 451.47%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 244.83%. Given Werewolf Therapeutics' higher possible upside, equities analysts plainly believe Werewolf Therapeutics is more favorable than Innate Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Innate Pharma
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Werewolf Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Summary

Innate Pharma beats Werewolf Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to TuHURA Biosciences?

Werewolf Therapeutics (NASDAQ:HOWL) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Werewolf Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.

TuHURA Biosciences has lower revenue, but higher earnings than Werewolf Therapeutics. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M17.58-$60.82M-$1.36N/A
TuHURA BiosciencesN/AN/A-$30.05M-$0.63N/A

Werewolf Therapeutics' return on equity of -158.82% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -158.82% -69.75%
TuHURA Biosciences N/A -182.40%-117.49%

In the previous week, Werewolf Therapeutics had 9 more articles in the media than TuHURA Biosciences. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 0 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.71 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Negative
TuHURA Biosciences Neutral

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 451.47%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 292.33%. Given Werewolf Therapeutics' higher probable upside, research analysts clearly believe Werewolf Therapeutics is more favorable than TuHURA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Werewolf Therapeutics beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HOWL vs. The Competition

Export
MetricWerewolf TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$33.05M$3.38B$6.24B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-0.5038.9229.0628.45
Price / Sales17.58158.54475.4361.47
Price / CashN/A57.8827.6236.52
Price / Book1.336.999.696.64
Net Income-$60.82M$23.62M$3.55B$332.53M
7 Day Performance-8.11%3.06%1.46%1.83%
1 Month Performance-32.67%6.56%5.35%8.98%
1 Year Performance-28.31%65.81%33.88%39.30%

Werewolf Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HOWL
Werewolf Therapeutics
2.6167 of 5 stars		$0.68
-1.4%		$3.75
+451.5%		N/A$33.05M$1.88MN/A40
CNTB
Connect Biopharma
2.8372 of 5 stars		$2.44
-0.6%		$8.67
+255.9%		N/A$137.63M$60KN/A110
ACOG
Alpha Cognition
3.418 of 5 stars		$6.30
-2.1%		$16.00
+154.2%		N/A$137.07M$10.22MN/AN/A
IMDX
Oncocyte
2.9162 of 5 stars		$4.23
+10.2%		$12.00
+183.7%		N/A$136.43M$4.05MN/A120
IPHA
Innate Pharma
3.4701 of 5 stars		$1.45
+3.5%		$5.00
+245.1%		N/A$135.95M$10.19MN/A220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel